other material
confidence high
sentiment positive
materiality 0.75
C4T Phase 1 cemsidomide in RRMM shows 53% ORR at RP2D, MRD negativity, well-tolerated
C4 Therapeutics, Inc.
- 53% ORR at 100 µg RP2D; 36% ORR across all doses (73 patients, median 7 prior lines).
- MRD negativity achieved in two patients at RP2D (sCR and CR); responses deepened over time.
- Median PFS 3.9 months (95% CI 3.2–5.6); median DOR 7.9 months (95% CI 3.0–NE).
- No treatment discontinuations related to cemsidomide; manageable neutropenia (58% Grade 3/4).
- ORR consistent across subgroups: prior CAR-T/TCE 53% at RP2D; prior BCMA 47% at RP2D.